Monomelic amyotrophy

Monomelic amyotrophy

WikiDoc Resources for Monomelic amyotrophy
Articles
Most recent articles on Monomelic amyotrophy Most cited articles on Monomelic amyotrophy Review articles on Monomelic amyotrophy Articles on Monomelic amyotrophy in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Monomelic amyotrophy Images of Monomelic amyotrophy Photos of Monomelic amyotrophy Podcasts & MP3s on Monomelic amyotrophy Videos on Monomelic amyotrophy
Evidence Based Medicine
Cochrane Collaboration on Monomelic amyotrophy Bandolier on Monomelic amyotrophy TRIP on Monomelic amyotrophy
Clinical Trials
Ongoing Trials on Monomelic amyotrophy at Clinical Trials.gov Trial results on Monomelic amyotrophy Clinical Trials on Monomelic amyotrophy at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Monomelic amyotrophy NICE Guidance on Monomelic amyotrophy NHS PRODIGY Guidance FDA on Monomelic amyotrophy CDC on Monomelic amyotrophy
Books
Books on Monomelic amyotrophy
News
Monomelic amyotrophy in the news Be alerted to news on Monomelic amyotrophy News trends on Monomelic amyotrophy
Commentary
Blogs on Monomelic amyotrophy
Definitions
Definitions of Monomelic amyotrophy
Patient Resources / Community
Patient resources on Monomelic amyotrophy Discussion groups on Monomelic amyotrophy Patient Handouts on Monomelic amyotrophy Directions to Hospitals Treating Monomelic amyotrophy Risk calculators and risk factors for Monomelic amyotrophy
Healthcare Provider Resources
Symptoms of Monomelic amyotrophy Causes & Risk Factors for Monomelic amyotrophy Diagnostic studies for Monomelic amyotrophy Treatment of Monomelic amyotrophy
Continuing Medical Education (CME)
CME Programs on Monomelic amyotrophy
International
Monomelic amyotrophy en Espanol Monomelic amyotrophy en Francais
Business
Monomelic amyotrophy in the Marketplace Patents on Monomelic amyotrophy
Experimental / Informatics
List of terms related to Monomelic amyotrophy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Monomelic amyotrophy (also known as MMA, Hirayama's disease, Sobue disease or Juvenile nonprogressive amyotrophy) is an untreatable, focal, lower motor neuron disease that primarily affects young (15 - 25 year-old) males in India and Japan. MMA is marked by insidious onset of muscular atrophy, which stabilizes at a plateau after two to five years from which it neither improves nor worsens. There is no pain or sensory loss associated with MMA. Unlike other lower motor neuron diseases, MMA is not believed to be hereditary and fasciculations (involuntary muscle twitches) are rare.

EMG tests reveal loss of the nerve supply, or denervation, in the affected limb without conduction block (nerve blockage restricted to a small segment of the nerve). Increased sweating, coldness and cyanosis have been reported for a few patients, indicating involvement of the sympathetic nervous system.

While MMA will cause weakness and/or wasting in only one limb, EMG and NCV tests often show signs of reinnervation in the unaffected limbs.

Treatment

There is no cure for MMA. Treatment consists of muscle strengthening exercises and training in hand coordination.

Prognosis

The symptoms of MMA usually progress slowly for one to two years before reaching a plateau, and then remain stable for many years. Disability is generally slight. Rarely, the weakness progresses to the opposite limb. There is also a slowly progressive variant of MMA known as O'Sullivan-McLeod syndrome, which only affects the small muscles of the hand and forearm and has a slowly progressive course.

Epidemiology

MMA occurs in males between the ages of 15 and 25. Onset and progression are slow. MMA is seen most frequently in Asia, particularly in Japan and India; it is much less common in North America.

External links

• Template:NINDS
• MND Association
• Overview at Washington University
• Gourie-Devi M, Nalini A (2001). "Sympathetic skin response in monomelic amyotrophy". Acta Neurol. Scand. 104 (3): 162–6. PMID 11551236.